The bioavailability of two fixed dose combination of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg was compared in two single-dose, randomized, open-label, 2-way, crossover bioequivalence studies with 52 Brazilian healthy male subjects. One study was under fasting conditions and the other one after a standard breakfast. Blood samples were taken predose and up to 96 h postdose and obtained plasma was frozen and kept until analysis. Plasmatic concentrations of dutasteride and tamsulosin were determined simultaneously using a validated UPLC-MS/MS method. Chromatographic separation was achieved with the chromatographic column UPLC BEH C18 and total run time was 3 minutes. Confidence intervals (CI90%) for the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC0-t) were calculated with log-transformed data. In the fasting bioequivalence study, the ratios and 90% CI for the geometric mean of dutasteride were 99.26% (93.07-105.86%) for Cmax and 102.49% (96.86-108.45%) for AUC0-t and the ratios and 90% CI for the geometric mean of tamsulosin were 102.39% (98.13-106.83%) for Cmax and 108.83% (102.49-115.57%) for AUC0-t. In the fed bioequivalence study, the ratios and 90% CI for the geometric mean of dutasteride were 92.42% (86.08-99.23%) for .08%) for AUC0-t and the ratios and 90% CI for the geometric mean of tamsulosin were 96.26% (89.86-103.11%) for Cmax e 95.88% (90.31-101.8%) for ASC0-t. At fasting and fed conditions, the test and reference formulations were considered bioequivalent since the 90% CIs for the geometric mean test/reference ratios were within a predetermined range of 80% to 125% (ANVISA).
INTRODUCTION
Benign prostatic hyperplasia (BPH) is a slowly progressive condition common in aging male. BPH manifests as lower urinary tract symptoms, including storage symptoms (e.g., urgency, frequency, nocturia) and voiding symptoms (e.g., hesitancy, a weak urine stream, and terminal dribbling) (1) . The combination of dutasteride and tamsulosin is indicated to treat and prevent BPH progression, by relieving symptoms, reducing prostate size (volume), improving the urine flow and reducing the risk of acute urinary retention (AUR) and the need of surgery related to BPH (2) . Dutasteride is a dual inhibitor of 5--reductase, because it inhibits type 1 and type 2 isoenzymes, which are responsible for the conversion of testosterone into 5--dihydrotestosterone (DHT). DHT is the main androgen responsible for hyperplasia of the prostatic glandular tissue. Tamsulosin hydrochloride is an antagonist of prostate -1A-adrenoreceptors, indicated for the treatment of functional symptoms of benign prostatic hyperplasia. Tamsulosin increases the urine flow through prostate and urethra muscle relaxation, relieving the obstruction (2) . Dutasteride is rapid absorbed and demonstrate dose proportionality in plasma concentrations. It has a bioavailability of 60% after oral administration and is highly plasma protein bound (>99.5%), mainly to albumin and 1-acid glycoprotein (1, 3) . After the administration of a single dose of 0.5 mg of dutasteride in fasting state, maximum serum concentrations occur within 1 to 3 hours. The bioavailability of dutasteride is not affect in the presence of food, but tmax is increased from 1-3 to 4-6 hours. Dutasteride is extensively metabolized by CYP3A4. After oral administration, 1.0 to 15.4% (average of 5.4%) of the dose taken is eliminated as dutasteride in feces. The remaining is eliminated through the same route as four main metabolites and six secondary metabolites. Only residual amounts of unchanged dutasteride (less than 0.1% of the dose) are detected in human urine. At therapeutic concentrations, the terminal half-life of dutasteride is 3 to 5 weeks (1, 2, 4) . The absolute bioavailability of tamsulosin MR in fasted humans is approximately 100%. The tmax is typically about 5 hours in the fasted state and about 6-8 hours in the fed state. Use on an empty stomach is associated with a slightly shorter tmax and a higher Cmax, but total drug exposure, as measured by the AUC, is similar. The plasma-protein binding of tamsulosin is high (>98%), the vast majority of the protein binding of tamsulosin is to 1-acid glycoprotein. Tamsulosin undergoes extensive hepatic metabolism via CYP3A4 and CYP2D6, but none of the primary metabolites are pharmacologically more active than the original compound. The apparent elimination half-life or tamsulosin from a modifiedrelease formulation is approximately 10-22 hours (1, 2, 4, 5) . The present studies were conducted to investigate the bioequivalence of two different fixed dose combinations of dutasteride plus tamsulosin hydrochloride 0.5/0.4 mg in healthy male subjects, under fast and fed conditions.
METHODS

Population
Fifty-two (52) volunteer subjects have been screened for each of the studies, all male among 18 and 50 years old. There were no restrictions regarding ethnical group. All volunteers were considered eligible to participate in the studies and were compliant with all inclusion and exclusion criteria expected in the protocols. All volunteers had good health conditions or absence of significant diseases, after evaluation of medical history, assessment of vital signs, physical examination, electrocardiogram and routine lab tests. All subjects enrolled in the studies had negative tests for hepatitis B (HBsAg and IgM Anti HBc), hepatitis C and HIV. 
Study Treatments
In both studies (fasting and fed conditions), the test formulation used was the combination in fixed dose containing dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg in extended release hard capsules (lot 22019), from Zodiac Produtos Farmacêuticos S.A., and the reference formulation was Combodart® 0.5+0.4 mg extended release hard capsules (lot 10367994A), from Glaxosmithkline Brasil Ltda.
Study Design
The studies have been performed through an openlabel, randomized, two-period, crossover and balanced design, with a washout period of 28 days between the administrations. In each period of the studies, volunteers received an extended release hard capsule containing 0. tamsulosin hydrochloride from one of the above mentioned formulations by oral route (dispensed in bottles protected from the light), taken as a single dose with a 200 mL glass of mineral water at room temperature. In the fasting conditions study, the drugs were administered after a minimum fasting of 8 hours.
In the fed conditions study, volunteers remained under fasting for at least 8 hours and received the study drug 30 minutes after the beginning of a standard breakfast. In both studies, volunteers remained under fasting for 4 hours after the administration of the drugs. In order to maintain the standardization of the treatment groups, diet (food and beverages) followed the same pattern for all subjects and in the two periods of each study. Alcoholic drinks and food or drinks containing caffeine or xanthine, such as coffee, tea, chocolate, and cola or guaraná soft drinks were not permitted. Blood samples (7.5 mL) were collected in coated tubes for light protection, containing EDTA as anticoagulant. The collection schedule in both studies included collections before (predose) and at 0:20; 0:40; 1:00; 1:30; 2:00; 2:30; 3:00; 3:30; 4:00; 4:30; 5:00; 5:30; 6:00; 6:30; 7:00; 7:30; 8:00; 9:00; 10:00; 12:00; 16:00; 24:00; 48:00; 72:00 and 96:00 hours after the administration of each drug. In both studies, right after the collections, blood samples were centrifuged at 3,500 rpm for 10 minutes at approximately 4°C. Immediately after centrifugation, plasma was separated and transferred to two amber cryogenic tubes previously labeled. The tubes were stored in ultra-low freezer at -70°C, and kept in this temperature until analysis. Clinical, analytical and statistical stages of the study were performed by Centro Avançado de Estudos e Pesquisas Ltda. (CAEP) located in the city of Campinas, São Paulo, Brazil.
Quantification of dutasteride and tamsulosin in human plasma
Plasma concentrations of dutasteride and tamsulosin have been determined simultaneously by reversedphase ultra-performance liquid chromatography with detection by sequential mass spectrometry (UPLC-MS/MS). Analytes were extracted from plasma by liquid-liquid extraction with liquid extractor Methyl tert-butyl ether. Dutasteride 13C6 and tamsulosin-d4 have been used as internal standard. In order to avoid inter-assay variations, all samples from every volunteer were analyzed in the same analytic run. The detection parameter used was the mass/charge (m/z) ratio between precursor and product ions. The quantification parameter was the ratio of the peak areas for analytes and internal standards. Dutasteride and tamsulosin concentrations in volunteers' samples were calculated by interpolation in the calibration curve. Chromatographic analysis was performed in an UPLC Acquity (Waters, USA) with Waters Acquity UPLC BEH C18 2.1 x 50 mm column (Waters, USA), with flow rate of 0.2 mL/min. The column was run at a temperature of 40°C, while auto injector was kept at 10°C. The mobile phase used was the mixture of ammonium acetate 10 mM+0.1% of formic acid and methanol, at a 25:75 (v/v) ratio. The injection volume was 7.5 μL and the total time of the run was fixed at 3.0 minutes. The detection by mass spectrometry was performed using electrospray ionization source in positive mode. (6) . The linearity range of the method for tamsulosin was 0.15 to 20 ng/mL and for dutasteride was 0.08 to 4.0 ng/mL. Validation parameters evaluated were selectivity, linearity, within-run and between-run precision, within-run and between-run accuracy, matrix effect, residual effect and drugs stability at different conditions.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic parameters have been obtained from plasma concentrations, versus time for dutasteride and tamsulosin and statistically analyzed to determine the bioequivalence, using the softwares Phoenix WinNonLin version 6.4 and Microsoft Excel version 2007. The area under the plasma concentration curve versus time was calculated by trapezoidal method, from time zero to the last measurable concentration (AUC0-t). The area under the plasma concentration curve versus time was also calculated from time zero to infinity (AUC0-∞), where AUC0-∞ = AUC0-t + Ct/Kel, and Ct is the last concentration of the drug experimentally determined and Kel is the terminal phase elimination rate constant. The maximum plasma concentration peak (Cmax) and the time to reach this peak (tmax) were obtained directly through plasma concentrations. The elimination half-life (t½) was determined by the equation t½ = 0.693/Kel. For the evaluation of bioequivalence between the two formulations, the parameters AUC and Cmax of the test drug and reference drug were used. Confidence Intervals, CI (90%) were created for the AUC and Cmax means ratio, of the transformed data of the test and reference drugs. The drugs are considered bioequivalent if the limits of the CI (90%) created for these ratios are higher than 80% and lower than 125%, as stated by ANVISA and FDA (7, 8) .
RESULTS
A total of 52 subjects entered each study, but 50 and 46 subjects completed the study under fast and fed conditions, respectively. Figure 1 (dutasteride -fasting), Figure 2 (tamsulosin -fasting), Figure 3 (dutasteride -fed), and Figure 4 (tamsulosin -fed). It can be observed that the curves were practically overlapped, showing an average pharmacokinetic profile similar for both drugs in both studies. Tables 1 (fasting conditions) and 2 (fed  conditions) . Tables 3 and 4 show the test/reference geometric means ratio of the pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ and the respective CI (90%) for the bioequivalence analysis of the studies. All CI (90%) were within the interval of 80% to 125%. 
DISCUSSION
In order to obtain a high sensitive and fast method for the quantification of dutasteride and tamsulosin in plasma, in the present work an UPLC-MS/MS method was developed and validated. In the presented method, the running time for chromatographic separation of a sample was 3.0 minutes and the quantification limit was 0.15 ng/mL for tamsulosin and 0.08 ng/mL for dutasteride, allowing the simultaneous sensitive and effective analysis of plasma concentrations of both drugs. statistical differences, when administered at the same molar dose of the active ingredient, under the same experimental conditions (9) . In the studies of the present article, the bioequivalence between two formulations of the combination in fixed dose containing dutasteride and tamsulosin was evaluated after oral administration to volunteers under fasting and after having a standard breakfast. The pharmacokinetic results (Cmax, AUC, tmax and t½) found in the studies for dutasteride and tamsulosin (Tables 1 and 2) were very similar to those reported by Kurczewski et al., 2017 (4) , for the commercially available combination in fixed dose containing dutasteride and tamsulosin 0.5/0.4 mg, from Glaxosmithkline, under fasting and fed conditions. As shown in Tables 3 and 4 
CONCLUSION
The results obtained shown that the test and the reference drugs containing dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg in extended release hard capsules are bioequivalent, thus, may be considered interchangeable in medical practice, because they have the same efficacy and safety profile for the patients.
